Amanta Healthcare IPO GMP: What Investors Should Know in Simple Words
The Amanta Healthcare IPO has become the new buzz in the stock market. People are talking because its GMP, or grey market premium, is already around ₹28 higher than the issue price of ₹126. In simple words, this means the stock could list at around ₹154, giving investors nearly 22% profit on day one if the demand continues.
The IPO opened on September 1 and will close on September 3, 2025. On the very first day, retail investors rushed in, and the IPO was fully booked within hours. Small investors subscribed more than three times, while non-institutional investors were close to filling their quota. Big institutional buyers (QIBs) have been a little slower, but the mood overall is very positive.
So why is everyone so interested? Amanta Healthcare is a pharmaceutical company from Gujarat. It makes sterile liquid medicines and medical devices, using modern packaging technology that makes the products safe and easy to store. The company has more than 320 distributors in India and also exports its products to Africa, Latin America, and even the UK.
Financially, the company has been improving. Last year its revenue stayed around ₹274 crore, but profits jumped sharply from ₹3.6 crore to ₹10.5 crore. This means Amanta Healthcare is becoming more efficient, with better margins and healthier returns for investors.
The money from the IPO, about ₹126 crore, will be used to build new manufacturing lines at its Gujarat plant. Around ₹70 crore will go into a new SteriPort line, and ₹30 crore will go into a small-volume parenteral (SVP) line. The rest will be used for general business needs. The company has also attracted anchor investors, who put in nearly ₹38 crore at the IPO price of ₹126 per share, which shows confidence from institutions.
But here’s the catch: the stock isn’t cheap. At the IPO price, the P/E ratio is about 47 times, which is much higher than other pharma companies that usually trade around 16–20 times. That’s why some experts are cautious. Anand Rathi has suggested “Subscribe for long-term,” seeing growth potential, while Arihant has called it “Neutral” because of the high valuation and execution risks.
For everyday investors, what does this mean? If you are looking for quick listing gains, the strong GMP suggests you may get them. But if you are planning for the long term, you’ll need to trust in Amanta Healthcare’s expansion and ability to grow profits, even at a higher price tag.
In short, the Amanta Healthcare IPO is like a hot ticket right now. The demand is strong, the GMP is encouraging, and the business looks promising. But just like any big purchase, it’s smart to look beyond the excitement and check if the price is worth it for your goals.
Post a Comment